Skip to content

S. 3794 · 119th Congress (2025–2027)

SAFE Drugs Act of 2026

This bill provides for increased oversight of drug compounding and imposes statutory limits on compounded drugs that are essentially copies of commercially available drugs.

Currently, subject to certain requirements, compounded drugs (i.e., drugs that are mixed or altered to meet patient needs) do not require Food and Drug Administration (FDA) approval. Additional limits apply to the compounding of drugs that are essentially copies of commercially available drug products.

Under the bill, a compounded drug is essentially a copy of a commercially available drug product if (1) the compounded drug contains any active ingredient found in a commercially available drug product, and (2) there is no change made for an individual patient that results in a significant difference between the compounded drug and the commercially available drug. (The FDA’s current definition of the term also addresses dosage strength and route of administration.)

The bill increases the frequency at which a licensed pharmacist or physician may compound a drug that is essentially a copy of a commercially available drug to 20 times per month. Current FDA policy allows four such prescriptions per month.

The bill also imposes annual reporting requirements on physicians, facilities, and pharmacies (except hospital-based pharmacies) that compound certain drug products for out-of-state patients more than 20 times per month. Further, the bill subjects certain large-scale outsourcing facilities (i.e., FDA-registered facilities that compound in bulk) to regular inspection and reporting requirements.

Show official title

A bill to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, and for other purposes.

Reported

This bill’s path

This is S. 3794’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

Sponsor
Sen. Jim Banks (R-IN)
Cosponsors
1 cosponsor

1 original · 0 later

  1. Sen. Martin Heinrich (D-NM)· Original · Feb 5, 2026
Policy area
Health
Subjects
  • Administrative law and regulatory procedures
  • Department of Health and Human Services
  • Drug safety, medical device, and laboratory regulation
  • Food and Drug Administration (FDA)
  • Government information and archives
  • Health personnel
  • Licensing and registrations
  • User charges and fees

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. Latest
    ▸ 3 committee actions · Feb 5, 2026 – Jul 27, 2026
    1. Referred to committee

      Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

      Sources
    2. Ordered reported

      Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.

      Sources
    3. Reported by committee

      Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.

      Sources

Committees

  1. SenateHealth, Education, Labor, and PensionsReferred Feb 5, 2026 · Markup Jul 22, 2026 · Reported Jul 27, 2026
    1. Jul 22, 2026 · Open business meeting

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Reported to Senate
Titles (3)
  1. SAFE Drugs Act of 2026

    Short title, Display title · Reported to Senate, Introduced in Senate

  2. Safeguarding Americans from Fraudulent and Experimental Drugs Act of 2026

    Short title · Reported to Senate, Introduced in Senate

  3. A bill to amend the Federal Food, Drug, and Cosmetic Act to further regulate compounding pharmacies and outsourcing facilities, and for other purposes.

    Official title · Introduced in Senate